The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Miami, Florida, United States
Unnamed facility
Miami Shores, Florida, United States
Improvement in the Investigator's Assessment of the pyoderma gangrenosum target ulcer
Time frame: Day 1 through Day 84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
Baltimore, Maryland, United States
Unnamed facility
Ann Arbor, Michigan, United States
Unnamed facility
Minneapolis, Minnesota, United States
Unnamed facility
Verona, New Jersey, United States
Unnamed facility
New York, New York, United States
Unnamed facility
Winston-Salem, North Carolina, United States
...and 9 more locations